Spots Global Cancer Trial Database for Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
Official Title: An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
Study ID: NCT00293111
Conditions
Interventions
Study Description
Brief Summary: An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients with Relapsed or Refractory Multiple Myeloma (MM)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Emory University School of Medicine, Atlanta, Georgia, United States
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
